Exhibit 99.1

PharmaFrontiers Corp. Names Brooks Boveroux to Board of Directors

    THE WOODLANDS, Texas--(BUSINESS WIRE)--Oct. 18,
2005--PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the
development and commercialization of cell therapies, announced that
Brooks Boveroux has been elected to serve as a member of its board of
directors. He will also join PharmaFrontiers' audit committee. Mr.
Boveroux, age 62, has held the post of vice president of finance for
several prominent biotechnology companies including Biogen, Inc.,
ImClone Systems, Inc. and The Liposome Company, Inc. His career spans
over two decades of senior level financial positions of both public
and private companies in the health care industry and his last
position was chief financial officer of Imcor Pharmaceutical Co., a
specialty pharmaceutical company, from which he retired in 2004.
    David McWilliams, chief executive officer of PharmaFrontiers
Corp., commented, "We are pleased to have Mr. Boveroux join our board
of directors. His broad experience in finance and background in health
care and pharmaceutical organizations will add significant value and
insight to the board."
    Mr. Boveroux received a Bachelor of Arts in English Literature
from Hamilton College and a Masters of Business Administration in
Finance from the Wharton Graduate Division, University of
Pennsylvania.

    About PharmaFrontiers Corp.

    PharmaFrontiers' strategy is to develop and commercialize cell
therapies to treat several major disease areas such as cardiac and
pancreatic conditions and Multiple Sclerosis. PharmaFrontiers owns
patented and proprietary individualized cell therapies that are in FDA
Phase I/II human dose ranging clinical trials to evaluate their safety
and effectiveness in treating MS. The company also holds the exclusive
worldwide license from the University of Chicago, through its prime
contractor relationship with Argonne National Laboratory, for patents
relating to the use of adult pluripotent stem cells derived from
patients' own circulating blood.

    Safe Harbor Statement

    This press release contains "forward-looking statements,"
including statements about PharmaFrontiers' growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that are
not historical facts or information. These forward-looking statements
are based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors, specifically
including those relating to PharmaFrontiers' ability to obtain
additional funding, develop its stem cell technologies, achieve its
operational objectives and obtain patent protection for its
discoveries that may cause PharmaFrontiers' actual results to be
materially different from any future results expressed or implied by
such forward-looking statements. PharmaFrontiers undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.

    CONTACT: PharmaFrontiers Corp.
             C. William Rouse, 281-775-0608
             brouse@pharmafrontierscorp.com
             or
             Investor Relations Contacts:
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             Bruce Voss, 310-691-7100
             bvoss@lhai.com
             or
             Media Relations Contact:
             Lippert/Heilshorn & Associates
             Mark Stuart, 310-691-7100
             mstuart@lhai.com